| 项目 | 2024年半年度计提金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 5,653,032.57 | 应收账款坏账损失、其他应收款坏账 损失、应收票据坏账损失 | | 资产减值损失 | 11,375,573.72 | 合同资产减值损失、存货跌价损失 | | 合计 | 17,028,606.29 | | 二、计提减值准备事项的具体说明 证券代码：688690 证券简称：纳微科技 公告编号：2024-062 苏州纳微科技股份有限公司 关于2024年半年度计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、2024 年半年度计提资产减值准备情况概述 根据《企业会计准则》及相关会计政策的规定，为客观、公允地反映公司截 至2024年6月30日的财务状况及经营成果，经公司及下属子公司对合并范围内可 能存在减值损失的各项资产进行了充分的评估和分析，根据谨慎性原则，公司对 相关资产进行了减值测试并计提了相应的减值准备。公司2024年半年度计提的各 类信用及资产减值准备合计 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, achieving a total of 500 million CNY, representing a 25% growth compared to the same period last year[2]. - The company's operating revenue for the first half of 2024 reached RMB 33,977.37 million, representing a 15.12% increase compared to RMB 29,516.03 million in the same period last year[15]. - The net profit attributable to shareholders for the first half of 2024 was RMB 4,505.21 million, a significant increase of 41.55% from RMB 3,182.77 million year-on-year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 3,653.52 million, which is an 88.89% increase compared to RMB 1,934.21 million in the previous year[15]. - The net cash flow from operating activities for the first half of 2024 was RMB 1,342.76 million, a recovery from a negative RMB 907.74 million in the same period last year[15]. - The company's total assets increased by 6.95% to RMB 227,438.06 million compared to RMB 212,656.83 million at the end of the previous year[15]. - The basic earnings per share for the first half of 2024 was RMB 0.1120, reflecting a 41.95% increase from RMB 0.0789 in the same period last year[16]. - The company's comprehensive gross margin for the first half of 2024 was 72.42%, a decrease of 6.64 percentage points from the previous year[17]. - The company achieved operating revenue of RMB 339.77 million, an increase of 15.12% compared to the previous year[17]. - The revenue impact from the consolidation of Fuli Instruments was RMB 56.92 million; excluding this, operating revenue decreased by 4.17% year-on-year[17]. Market Outlook and Growth Strategies - The company provided a positive outlook for the second half of 2024, projecting a revenue growth of 30% based on new product launches and market expansion strategies[2]. - The company is expanding its market presence in Southeast Asia, targeting a 20% market share within the next two years[2]. - New product development includes the introduction of advanced nanomaterials, expected to contribute an additional 100 million CNY in revenue by the end of 2024[2]. - The company plans to invest 50 million CNY in research and development for innovative technologies in the upcoming fiscal year[2]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 500 million allocated for potential deals[123]. - Market expansion plans include entering three new international markets by the end of 2024, targeting a 10% market share in each[123]. Research and Development - The R&D expenditure as a percentage of operating revenue was 22.68%, a decrease of 5.56 percentage points from 28.24% in the previous year[16]. - The company reported a total R&D investment of ¥7,707.69 million, a decrease of 7.53% compared to ¥8,335.58 million in the same period last year, with R&D investment accounting for 22.68% of operating revenue, down by 5.56 percentage points[43]. - The company has developed proprietary technologies for the precise preparation of monodisperse microspheres, enabling customized production based on application needs[24]. - The company has developed a comprehensive technology system for precise preparation of microspheres, enabling customization of size, morphology, and surface properties[27]. - The company is actively exploring market expansion opportunities and new product development in the field of biopharmaceuticals and diagnostics[33]. Acquisitions and Strategic Moves - A strategic acquisition of a competitor in the analytical instruments sector was completed, expected to enhance the company's product offerings and increase market competitiveness[2]. - The company completed the acquisition of Fuli Instruments, enhancing its competitive analysis solutions by integrating chromatography instruments with consumables[24]. - The company acquired Fuli Instruments in March 2024, enhancing its capabilities in chromatography instruments and providing integrated solutions for life sciences and other industries[27]. - The company completed the acquisition of 44.80% equity in Zhejiang Fuli Analytical Instrument Co., Ltd. for a total investment of RMB 179,200,104.00, making it a consolidated subsidiary as of March 2024[86]. Risks and Challenges - The management highlighted potential risks related to supply chain disruptions, which could impact future performance if not addressed[4]. - The company expects to face challenges in meeting the performance assessment for the third vesting period of the 2022 restricted stock incentive plan[17]. - The company faces risks related to the theft of proprietary technology and the potential loss of key R&D personnel, which could impact its competitive edge[66]. - Increased competition from both domestic and international firms in the chromatography materials market is a significant risk, necessitating enhanced R&D and market responsiveness[68]. Environmental and Compliance - The company has implemented carbon reduction measures, including the investment in organic solvent recovery systems at two facilities, effectively reducing carbon emissions during production[113]. - The company has maintained a 100% compliance rate for all monitored pollutants during the reporting period[107]. - The company has developed an emergency response plan for environmental incidents, which has been filed with local environmental authorities[106]. - The company is classified as a key pollutant discharge unit and has met all national and local pollutant discharge standards[100]. Shareholder and Governance Matters - The board has approved a share buyback program worth 100 million to enhance shareholder value[123]. - The company commits to avoiding related party transactions and will conduct any necessary transactions at fair market prices, adhering to legal and regulatory requirements[126]. - The company will not transfer or delegate management of shares held prior to the IPO for 36 months post-listing, nor will it repurchase those shares[128]. - The company will bear legal responsibility for any losses incurred by the company or investors due to non-compliance with share lock-up commitments[128]. - The company has not proposed any profit distribution or capital reserve transfer plans for the reporting period[96].

证券代码：688690 证券简称：纳微科技 公告编号：2024-060 苏州纳微科技股份有限公司 2024年半年度募集资金存放及使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"证监会"）《上市公司监管指引 第2号——上市公司募集资金管理和使用的监管要求》（证监会公告[2012]44号） 《上海证券交易所科创板上市公司自律监管规则适用指引第 1 号——规范运作》 的规定，公司编制了截至 2024 年 6 月 30 日的《募集资金存放与实际使用情况专 项报告》。 一、募集资金基本情况 2021 年首次公开发行股票实际募集资金基本情况： 经中国证券监督管理委员会证监许可[2021]1395号文核准，本公司于2021年 6 月向社会公开发行人民币普通股（A 股）4,400 万股，每股发行价为 8.07 元， 应募集资金总额为人民币 35,508 万元，根据有关规定扣除发行费用 4,714.39 万 元后，实际募集资金金额为 30,793.61 万元。该募集资金已于 2021 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-063 苏州纳微科技股份有限公司 第三届监事会第二次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 苏州纳微科技股份有限公司（以下简称"公司"）第三届监事会第二次会议 于 2024 年 8 月 26 日以线上方式召开。会议应出席监事 3 名，实际出席 3 名，符 合《中华人民共和国公司法》和《苏州纳微科技股份有限公司章程》的有关规定， 会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2024 年半年度报告>及摘要的议案》 经审议，监事会确认公司 2024 年半年度报告的编制和审议程序符合法律、 法规、《公司章程》和公司内部管理制度的各项规定；公司 2024 年半年度报告的 内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规定，所包含 的信息能从各方面客观、真实、公允地反映出公司 2024 年半年度的经营管理和 财务状况等事项；监事会成员能够保证公司 2024 年半年度报告所披露的信息真 实 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-059 苏州纳微科技股份有限公司 关于控股子公司对其参股公司提供担保 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 被担保人：苏州纳微科技股份有限公司（以下简称"公司"）控股子公 司苏州赛谱仪器有限公司（以下简称"赛谱仪器"）的参股公司苏州赛正仪器科 技有限公司（以下简称"赛正科技"）。 本次担保金额：赛正科技于2023年9月通过招拍挂程序取得苏州工业园区 星湖街东、唯新路南11,249.93平方米土地使用权，为顺利推进在该土地上建设 厂房，赛正科技拟向银行申请不超过人民币7,500万元的在建工程贷款，贷款期 限为10年，赛正科技股东苏州正得利环保技术服务有限公司（以下简称"正得 利"）及赛谱仪器拟根据各自出资比例为赛正科技上述贷款事项提供连带保证责 任，赛谱仪器对赛正科技提供担保额度不超过人民币3,675万元。截止本公告披 露日，公司及控股子公司对赛正科技的担保余额为人民币0元。 本次担保无反担保，公司无逾期对外担保的情形 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-058 苏州纳微科技股份有限公司 关于控股子公司对其参股公司增资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 苏州纳微科技股份有限公司（以下简称"公司"）控股子公司苏州赛谱 仪器有限公司（以下简称"赛谱仪器"）拟向其参股公司苏州赛正仪器科技有限 公司（以下简称"赛正科技"）增资人民币735万元，认购赛正科技735万元注册 资本，赛正科技另一股东苏州正得利环保技术服务有限公司（以下简称"正得 利"）拟等比例向赛正科技增资人民币765万元，认购赛正科技765万元注册资 本，增资后赛正科技注册资本由1,000万元增加至2,500万元，赛谱仪器持有的赛 正科技的注册资本比例为49%，持股比例未发生变动。本次增资后赛正科技仍为 赛谱仪器的参股公司，不影响公司合并范围。 本次增资构成关联交易，不构成重大资产重组。 本次关联交易已经公司第三届董事会第二次会议及第三届监事会第二次 会议审议通过，关联交易事项在提交董事会前已经第三届董事会独立 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-056 苏州纳微科技股份有限公司 关于涉及诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 2023 年 8 月 31 日，公司收到苏州市中级人民法院送达的《起诉状》与《变 更诉讼请求申请书二》，韩寒先生的诉讼请求变更为：（1）判令确认 原告以 38,273,600 元的对价，享有被告一苏州纳百持有苏州纳研的财产份额 4,230,240 元；（2）判令被告一苏州纳百向原告支付针对 2,656,580 股激励股份的收购价款 122,909,330.28 元，并承担资金占用损失；（3）被告二 BIWANG JACK JIANG 对苏 州纳百的付款义务承担连带责任；（4）本案诉讼费用、保全费用由二被告共同承 担。 具体内容详见公司于 2023 年 9 月 1 日在上海证券交易所网站 （www.sse.com.cn）披露的《苏州纳微科技股份有限公司关于涉及诉讼进展的公 告》（公告编号：2023-054）。 重要内容提示： 判决结果：1、被告苏州纳百管理咨 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-055 苏州纳微科技股份有限公司 进展情况，现将公司回购股份进展情况公告如下： 截止2024年7月31日，公司通过上海证券交易所系统以集中竞价交易方式累计 回购公司股份2,928,822股，占公司总股本403,814,765股的比例为0.73%，回购成 交的最高价为22.18元/股、最低价为16.48元/股，支付的资金总额为人民币 58,746,772.36元（不含印花税、交易佣金等交易费用）。 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 士提议 | | --- | --- | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购用途 | 用于员工持股计划或股权激励 | | 累计已回购股数 | 万股 292.8822 | | 累计已回购 ...

证券代码：688690 证券简称：纳微科技 公告编号：2024-054 苏州纳微科技股份有限公司 关于涉及诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 原告：韩寒先生 被告一：苏州纳百管理咨询有限公司（以下简称"苏州纳百"） 被告二：BIWANG JACK JIANG 一、本次诉讼的基本情况 2022 年 12 月 5 日，公司收到苏州市中级人民法院送达的关于韩寒先生起诉 公司、苏州纳百及公司董事长 BIWANG JACK JIANG（江必旺）先生等三方的《民 事起诉书》等相关材料。韩寒先生起诉要求（1）确认以 51,556,500 元的对价享 有苏州纳百持有苏州纳研的财产份额 5,698,350 元；（2）要求公司向韩寒先生支 付针对 2,656,580 股激励股份的收购价款 122,909,330.28 元，并承担资金占用损 失。 具体内容详见公司于 2022 年 12 月 7 日在上海证券交易所网站 （www.sse.com.cn）披露的《苏州纳微科技股份有限公司关于涉及诉讼的公告》 ...

Financial Performance - The company expects to achieve a net profit attributable to shareholders of approximately RMB 45.04 million for the first half of 2024, an increase of about RMB 13.21 million or 41.51% compared to the same period last year [3]. - The company anticipates a net profit of approximately RMB 36.52 million after deducting non-recurring gains and losses for the first half of 2024, representing an increase of about RMB 17.18 million or 88.83% year-on-year [9]. - The company's revenue for the first half of 2023 was RMB 295.16 million, with a net profit attributable to shareholders of RMB 31.83 million [10][20]. - The company projects a revenue of approximately RMB 339.77 million for the first half of 2024, an increase of about RMB 44.61 million or 15.12% compared to the same period last year [18]. Product Sales - The sales revenue of chromatography fillers and chromatography media products is expected to be approximately RMB 199.40 million for the first half of 2024, a year-on-year decrease of about 5.46% [22]. - The company completed the acquisition of 44.80% equity in Zhejiang Fuli Analytical Instrument Co., which contributed approximately RMB 57.05 million to the consolidated revenue for the reporting period [13]. Research and Development - The company's R&D investment for the first half of 2024 is approximately RMB 77.08 million, accounting for about 22.68% of its revenue [22]. - The company launched innovative products such as nucleic acid synthesis carrier microspheres and the next-generation affinity chromatography medium NMab Titan in the first half of 2024 [22]. Cost Management - The company has reduced its share-based payment expenses to approximately RMB 22.90 million, a decrease of about 63.86% compared to the same period last year [2]. Performance Forecast - The company has not identified any significant uncertainties that would affect the accuracy of this performance forecast [23].